- Home
- BLRX vs GGRP Comparison
BLRX vs GGRP Comparison
Compare BLRX & GGRP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.55
N/A
Current Price
$0.60
Company Overview
Basic Information| Metric | BLRX | GGRP |
|---|---|---|
| Founded | 2003 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 12.5M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BLRX | GGRP |
|---|---|---|
| Price | $2.55 | $0.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | 8.4K | ★ 52.5K |
| Earning Date | 03-23-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $72.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $0.54 |
| 52 Week High | $7.77 | $0.65 |
Technical Indicators
Market Signals| Indicator | BLRX | GGRP |
|---|---|---|
| Relative Strength Index (RSI) | 44.86 | 47.30 |
| Support Level | $2.66 | $0.55 |
| Resistance Level | $3.93 | $0.64 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 33.76 | 37.02 |
Price Performance
Historical Comparison BLRX
GGRP
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.